Will EFU Health, Jubilee General, Adamjee Insurance, and State Life Health cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Darzalex is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by DRAP?

The DRAP named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DRAP review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Pakistani-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. Pakistan Medical and Dental Council (PMDC) and DRAP verifies the active license; the DRAP application records both the prescribing physician and the dispensing facility.

Can I receive Darzalex at home?

The dispensing facility must be Pakistani-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 3,000 to 5,000 per dose (cycle-dependent frequency). Delivered quote within 24h.Get my quote

Darzalex access in Pakistan: the DRAP named-patient pathway

How patients in the Islamic Republic of Pakistan legally obtain Darzalex (daratumumab) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Pakistan access Darzalex (daratumumab) for multiple myeloma in newly diagnosed and relapsed/refractory settings in combination regimens, and light-chain amyloidosis, under the FDA label through the DRAP named-patient pathway, a Drug Regulatory Authority of Pakistan-administered mechanism that allows a Pakistani-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in PKR.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Darzalex reaches patients in Pakistan

Darzalex (daratumumab, anti-CD38 monoclonal antibody, FDA-approved 2015 for multiple myeloma with subsequent label expansions through newly diagnosed combinations and light-chain amyloidosis; Darzalex Faspro subcutaneous form FDA-approved 2020) is partially visible on the DRAP registered-product verification portal at dra.gov.pk/e-services/online-data-verification through the Janssen distribution channel, but specific presentations, dose strengths, and combination-regimen indications are not always available in stocked form. Where the prescribed dose, formulation (IV versus SC Faspro), or combination indication does not match locally stocked product, Pakistani patients access Darzalex through the Special Permission for Import of Therapeutic Goods for Personal Use, administered by DRAP's QA and LT Division Import and Export Section under the Drugs Act 1976. The application is filed at dra.gov.pk/therapeutic-goods/import-export/special-permissions. The Darzalex-specific clinical justification must document: multiple myeloma stage (ISS or R-ISS), prior lines of therapy, intent to combine with bortezomib, lenalidomide, dexamethasone, or other backbone, and infusion-related-reaction pre-medication plan. For Darzalex Faspro (subcutaneous), the dispensing setting can be ambulatory; for IV daratumumab, infusion-chair capacity is required. DRAP processing for named-patient imports is typically several working days. Cold-chain handling (2 to 8 degrees Celsius) is required throughout; the application package documents the cold-chain plan.

Where Darzalex is administered in Pakistan

Darzalex IV requires infusion-capable medical oncology or haematology day-care with pre-medication and slow first-infusion protocols; Darzalex Faspro SC requires ambulatory injection capacity with monitoring. Pakistani tertiary haematology and oncology centres handling Darzalex include the Aga Khan University Hospital (AKUH) Department of Haematology and Medical Oncology in Karachi at hospitals.aku.edu, which runs a structured multiple myeloma service with BMT capability; Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH and RC) Medical Oncology and Haematology in Lahore (with Peshawar and Karachi branches) at shaukatkhanum.org.pk; the National Institute of Blood Diseases and Bone Marrow Transplantation (NIBD) in Karachi, the country's largest haematology-focused tertiary; the Indus Hospital Haematology and Oncology Services in Karachi at indushospital.org.pk; and Jinnah Postgraduate Medical Centre (JPMC) Department of Oncology in Karachi as the major public-tertiary node. NIBD and AKUH are the most frequent BMT and autologous stem cell transplant referral nodes for newly-diagnosed transplant-eligible myeloma where Darzalex-containing induction is the FDA-label standard.

What Darzalex costs in Pakistan

The US reference WAC for Darzalex IV is approximately USD 6,500 to USD 8,000 per 400 mg vial; standard induction regimens (16 mg/kg weekly then biweekly then monthly) drive monthly drug costs in the USD 15,000 to USD 25,000 range during induction and USD 8,000 to USD 12,000 during maintenance per Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Darzalex Faspro (1,800 mg single-dose subcutaneous) WAC is approximately USD 10,500 to USD 12,000 per dose. Annual cost ranges USD 130,000 to USD 250,000 depending on regimen and duration. Limited local-currency benchmarks for Darzalex in PKR have appeared in Pakistani pharmacy-distributor channels (typical brand: Darzalex by Janssen) where the drug is locally stocked, but no consistent public MRP database disclosure is observed as of 2026-05-31; do not estimate locally-stocked-versus-imported variance. Price snapshot: 2026-05-31. Cost layers: cold-chain international logistics into Pakistan (mid four-figure USD range for biologic, refrigerated lanes), DRAP permit and customs duties (nominal), the dispensing hospital's infusion-administration and pre-medication fees, and the Reserve Meds concierge fee itemised separately.

Funding and access barriers for Darzalex in Pakistan

Multiple myeloma is a relatively common haematologic malignancy in Pakistan (incidence estimated approximately 2 to 3 per 100,000 annually). The Sehat Sahulat Programme inpatient cover may extend to selected myeloma inpatient admissions; outpatient daratumumab maintenance is not consistently covered at the federal-card level. Khyber Pakhtunkhwa Sehat Card Plus has the broadest specialty cover and has historically funded selected oncology biologics on a case-by-case basis. Pakistan Bait-ul-Mal at pbm.gov.pk grants oncology cases case-by-case. Major private insurers (Jubilee Life, EFU Life, State Life, Adamjee Life) do not publish a daratumumab formulary line; corporate group policies with high-cost rider may cover an induction course subject to step-therapy documentation (bortezomib-lenalidomide-dexamethasone backbone failure or contraindication). Janssen Pakistan operates a patient-support programme through local distribution channels for locally-registered presentations; this does not extend to imported presentations or unregistered indication combinations. The SKMCH Zakat fund and Indus Hospital charity model fund myeloma cases under their respective access criteria. The DRAP cold-chain customs experience for biologics requires the importing entity to document temperature logging from origin to port, but Pakistani customs operates 24-hour clearance for documented therapeutic goods at major ports (Karachi, Lahore, Islamabad airports).

Recent regulatory and access news for Darzalex

FDA approved (July 2024) Darzalex Faspro plus bortezomib, lenalidomide, and dexamethasone (D-VRd) for newly diagnosed multiple myeloma in transplant-eligible adults based on the PERSEUS trial; the expanded label establishes a daratumumab-containing quadruplet as the new FDA-label standard induction for transplant-eligible newly diagnosed myeloma. The PERSEUS data are summarised in the FDA approval letter at accessdata.fda.gov/scripts/cder/daf. FDA also expanded the Darzalex Faspro label (August 2024) to include high-risk smouldering multiple myeloma. No DRAP-specific bulletin on Darzalex over the last 12 months has been observed as of 2026-05-31. The DRAP consolidated Guidance Document for Imports and Exports at dra.gov.pk regulatory updates remains the operative procedural reference.

Where Reserve Meds fits in Darzalex cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DRAP, and we do not replace your dispensing pharmacy. For Darzalex specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Pakistan, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Darzalex case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DRAP application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Pakistani haematology at SKMH and AKU handles anti-CD38 myeloma therapy under DRAP Special Permission with structured infusion monitoring.

Next step

If your Pakistani physician has prescribed Darzalex and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Darzalex case Or message us on WhatsApp